SCHEMBL14816248

SCHEMBL14816248

COc1ccc(COc2cn(-c3cccc(Br)c3)c([C@H](C)O)cc2=O)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 3/20 0.46
COMT P21964 2/20 0.43
RPA1 P27694 1/20 0.39
LRRK2 Q5S007 2/20 0.39
MAOB P27338 2/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KMT2A Q03164 2/20 0.38
ALDH1A1 P00352 1/20 0.38
CCR5 P51681 1/20 0.38
SMPD1 P17405 1/20 0.38
PARP15 Q460N3 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
PDE4A P27815 1/20 0.38
KCNH2 Q12809 1/20 0.38
MEN1 O00255 1/20 0.37
NPBWR1 P48145 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2464801 1.00 PTGER1 (0.46) PTGER1COMTRPA1LRRK2MAOB
SCHEMBL14816211 1.00 PTGER1 (0.46) PTGER1COMTRPA1LRRK2MAOB
SCHEMBL2462545 0.89 PTGER1 (0.43) PTGER1RPA1LRRK2MAOBLMNA
SCHEMBL2463639 0.84 PTGER1 (0.45) PTGER1COMTRPA1LRRK2MAOB
SCHEMBL2467784 0.82 NPC1 (0.45) PTGER1LRRK2MAOBLMNAMAPT
SCHEMBL2466974 0.78 CYP11B1 (0.44) PTGER1COMTLMNAMAPTKMT2A
SCHEMBL9357275 0.78 NPC1 (0.44) MAPTALDH1A1HDAC8
SCHEMBL9357282 0.78 NPC1 (0.44) MAPTALDH1A1HDAC8
SCHEMBL14815708 0.76 COMT (0.38) COMTLMNAMAPTKMT2AALDH1A1
SCHEMBL2467889 0.73 COMT (0.49) PTGER1COMTMAOBKMT2ACCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2542076-B1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MERCK SHARP & DOHME (US) 2021-01-13 EP disclosed
US-9399651-B2 Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders Merck, Sharp & Dohme Corp. (US) 2016-07-26 US disclosed
US-20150299227-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MERCK SHARP & DOHME CORP. (US) 2015-10-22 US disclosed
US-9024032-B2 Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders MERCK SHARP & DOHME CORP. (US) 2015-05-05 US disclosed
US-20130084346-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MERCK SHARP & DOHME LLC 2013-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299227-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS COMT, PNMT, TPMT PTGER1 1145/4885COMT 1/4885RPA1 3920/4885
US-20130084346-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS COMT, PNMT, TPMT PTGER1 1145/4885COMT 1/4885RPA1 3920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.